Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy

References

• Huang C-Q, Min Y, Wang S-Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017;8(33):55657–55683.
   PubMedGoogle Scholar
• Passot G, Bakrin N, Isaac S, et al. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies. Eur J Surg Oncol. 2014;40:957–962.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies. Ann Surg. 2011;253:764–768.
   PubMed Web of Science ®Google Scholar
• Tan GHC, Shannon NB, Chia CS, et al. Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperthermia. 2018;34:595–600.
   PubMed Web of Science ®Google Scholar
• Ye J, Ren Y, Wei Z, et al. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: a retrospective cohort study. Surg Oncol. 2018;27:456–461.
   PubMed Web of Science ®Google Scholar
• Park JT. Postoperative acute kidney injury. Korean J Anesthesiol. 2017;70:258–266.
   PubMed Web of Science ®Google Scholar
• Bihorac A, Yavas S, Subbiah S, et al. Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg. 2009;249:851–858.
   PubMed Web of Science ®Google Scholar
• Baradaran A, Tavafi M, Ardalan MR, et al. Cisplatin; nephrotoxicity and beyond. Ann Res Antioxid. 2016;1:e014.
   Google Scholar
• Somashekhar SP, Prasanna G, Jaka R, et al. Hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a single institution Indian experience. Natl Med J India. 2016;29:262–266.
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Breakiet M, Azzam A, et al. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail. 2014;36:1486–1491.
   PubMed Web of Science ®Google Scholar
• Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25:47–58.
   PubMed Web of Science ®Google Scholar
• Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24:3338–3344.
   PubMed Web of Science ®Google Scholar
• Badgwell B, Blum M, Das P, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2018;32:512.
   PubMed Web of Science ®Google Scholar
• Newhook TE, Agnes A, Blum M, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol. 2019.
   Web of Science ®Google Scholar
• Agarwal A, Dong Z, Harris R, et al. Cellular and molecular mechanisms of AKI. J Am Soc Nephrol. 2016;27:1288–1299.
   PubMed Web of Science ®Google Scholar
• Hallqvist L, Granath F, Huldt E, et al. Intraoperative hypotension is associated with acute kidney injury in noncardiac surgery: an observational study. Eur J Anaesthesiol. 2018;35:273–279.
   PubMed Web of Science ®Google Scholar
• Cata JP, Zavala AM, Van Meter A, et al. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study. Int J Hyperthermia. 2018;34:538–544.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14:2550–2558.
   PubMed Web of Science ®Google Scholar
• Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–869.
   PubMed Web of Science ®Google Scholar
• Bouhadjari N, Gabato W, Calabrese D, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin: amifostine prevents acute severe renal impairment. Eur J Surg Oncol. 2016;42:219–223.
   PubMed Web of Science ®Google Scholar
• Saxena A, Valle SJ, Liauw W, et al. Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017;115:417–424.
   PubMed Web of Science ®Google Scholar
• Ikoma N, Chen HC, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679.
   PubMed Web of Science ®Google Scholar
• Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:4332.
   PubMed Web of Science ®Google Scholar
• Hobson C, Singhania G, Bihorac A. Acute kidney injury in the surgical patient. Crit Care Clin. 2015;31:705–723.
   PubMed Web of Science ®Google Scholar
• Pfeifle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol. 1985;3:237–244.
   PubMed Web of Science ®Google Scholar
• Elazzazy S, El-Geed HA, Al Yafei S. Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin's lymphoma: a case report. Int Med Case Rep J. 2013;6:1–5.
   PubMedGoogle Scholar
• Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. Crit Care. 2012; 16:313.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Caroen S, Oronsky A, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations, and management. Cancer Chemother Pharmacol. 2017;80:895–907.
   PubMed Web of Science ®Google Scholar
• Goltzman D. Clinical manifestations of hypocalcemia. In Mulder JA, editor. UpToDate. [Retrieved 2018 Sep 12]. Available from: https://www.uptodate.com/contents/clinical-manifestations-of-hypocalcemia
   Google Scholar
• Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10:1257–1272.
   PubMed Web of Science ®Google Scholar